Navigation Links
Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
Date:11/2/2010

RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2010 /PRNewswire/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years.  PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. 

PROLASTIN-C has replaced PROLASTIN in Canada. Both products are indicated for chronic augmentation and maintenance therapy in adults who have emphysema due to a genetic condition known as alpha1-antitrypsin (AAT) deficiency. The active protein in PROLASTIN-C increases or "augments" protein levels in AAT-deficient patients.

"Talecris research and development scientists continually strive to enhance the overall quality of our products by incorporating the latest advances in technology," said Joel Abelson, Senior Vice President & General Manager, Portfolio Management & International Business. "PROLASTIN-C is an example of our commitment to supporting patients who use protein therapies to treat their rare and life-threatening conditions."

PROLASTIN-C contains the same active ingredient as PROLASTIN. Clinical studies demonstrated that the products are equally effective at raising alpha1 levels, and that PROLASTIN-C has an adverse event profile consistent with that of PROLASTIN.  (http://www.biomedcentral.com/1472-6904/10/13

The most common drug-related adverse reactions during clinical trials in >/=1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus. The most serious adverse reaction observed during clinical studies with PRO
'/>"/>

SOURCE Talecris Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
2. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
3. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
4. Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
5. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
6. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
7. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, announced today that it will attend ... Fuzhou, China between October 31 and November 3, 2011. ... products from its three primary business segments: patient monitoring ...
... SINGAPORE, Oct. 25, 2011 S*BIO Pte Ltd today announced ... its novel JAK2 inhibitor pacritinib (SB1518), in the first half ... the treatment of myelofibrosis (MF). The company is actively exploring ... "Data from Phase 1 and 2 clinical ...
Cached Medicine Technology:Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 2Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair 3S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) 2
(Date:8/31/2015)... ... 31, 2015 , ... Three Bakers Gluten Free Bakery launched the redesign of ... and easy-to-find information on their offering of gluten-free breads and pizzas, living without gluten, ... way for us to share information about our gluten free product offerings, but also ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo is pleased ... Terrace Outdoor Sauna. After months of extensive engineering and design of our newest sauna ... withstand the elements and is offered at a very attractive price-point. , Before ...
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ON ... (aka Dr. Luciana) received a total of three Silver Medal awards at ... Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del Weston, ...
(Date:8/31/2015)... ... 31, 2015 , ... American Family Care (AFC), the nation’s ... presence in Tennessee with the opening of a new urgent care facility at ... sixteenth in Tennessee, and 148th in the U.S. overall. , “We’re excited to ...
(Date:8/31/2015)... ... , ... The more hours young adults spend watching television each day, the ... circumference, a 15-year analysis by the University of Pittsburgh Graduate School of Public Health ... young adulthood is an important time to intervene and promote less television viewing, according ...
Breaking Medicine News(10 mins):Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3
... 2 Vista Partners announced,today that it has ... RPTP). "We believe Raptor,s operational approach will serve,as ... as it promotes,operational efficiency, reduced operating costs and ... a Phase II candidate for 2008 in,Convivia(TM), which ...
... 1 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced ... of its common stock at a public offering price ... offered by Arena. The underwriters,have a 30-day option to ... to cover over-allotments, if any. CIBC World Markets ...
... Nov. 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... that it will present at,the following conferences: * The ... Tuesday November 6, 2007 at 2:20 PM ... New York, NY., * The CIBC 18th Annual ...
... 1 Otter Tail,Corporation (Nasdaq: OTTR ) announced financial results ... -- Record third quarter revenues of $302.2 million. -- Consolidated ... compared with $13.5 million for the third ... for the third quarter of 2007 compared ...
... Calif., Nov. 1 Masimo, the inventor,of Pulse ... announced the completion of CHN,s system-wide implementation of,Masimo ... of superior,Masimo SET performance in other areas of ... pulse oximetry technology to virtually every site --,making ...
... Nov. 1 Talent retention, employee,engagement and retirement ... of,human resources executives in the Best Practices, LLC,s ... in surveys to networking events, roundtable discussions and,information ... that helped them succeed this year. As ...
Cached Medicine News:Health News:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. 2Health News:Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 3Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 4Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 5Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 6Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 7Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 8Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 9Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 10Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 11Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 12Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 13Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 14Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 15Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Retain Talent and Engage Employees in 2008 2
... technology enables a fast, precise patternless edge ... Introducing the TOPCON ALE-X1. The latest advance ... of improved features and functions. High-speed processing, ... and beveled edges, precise three-dimensional frame tracing ...
Inquire...
Inquire...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
Medicine Products: